Prot #IRB17-0547/NU UC20L05: A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study)

Project: Research project

Project Details

StatusActive
Effective start/end date1/11/21 → 1/11/26

Funding

  • The University of Chicago ((OE) Prot #IRB17-0547/NU UC20L05 // (OE) Prot #IRB17-0547/NU ...)
  • Bristol-Myers Squibb Company ((OE) Prot #IRB17-0547/NU UC20L05 // (OE) Prot #IRB17-0547/NU ...)